GSK3B and Alzheimer disease: The results of systemic review showed that the levels of platelet immunoglobulin, APP-N, BACE (36 kDa/BACE 57 kDa), matrix metalloproteinases-9 (MMP-9), MMP-2, platelet membrane fatty acids, phospholipase C (PLC), phenolsulphotransferase (PST), plasma-derived growth factor (PDGF), C-type lectin-like receptor 2(CLEC2), extracellular vesicles (EVs), glycogen synthase kinase 3-beta (GSK3β) ratios were significantly different between AD patients and controls (Fig. 3), but further studies were needed to verify the alterations of these markers in AD patients.